Opinions
Michael Smedley
Patient Home Monitoring
PHM-X
COMMENT
Jul 14, 2017
Stock price when the opinion was issued
You might be interested:
Just announced they will be splitting into 2 companies. Made a fair number of missteps over the past 1-3 years. Bought a respiratory type of company, integrated it, and then decided to spin it out. He is not sure why they went this route. It was already a small company to begin with, and now you have 2 companies below $100 million market cap. Usually you want a company above that level, because that’s when fund managers can buy the stock and analysts start to cover it. Doesn't feel there was a big "value add" for splitting these 2 out. Wait for a quarter or 2 to see what the results look like. He is not a big fan of either company.
This was making a number of acquisitions. One of the biggest was Sleep Management. About a year ago they announced they were going to spin the business off into 2 different segments, one company being Sleep Management, and the other would be the rest of their companies. Viamed will be the old Sleep Management and the rest will be under Apparo Home Care. Sleep Management appears to be growing the fastest with about 20% annual growth. This is trading at a fairly cheap multiple of their cash flow and earnings.
Take some profits or be a buyer? This has contracted a bit again. The main problem is that you don’t really get too much presence of them in the marketplace compared to their beginning. An issue that is difficult to handle is that they are going to split into 2 companies in a few months. When they split, that would suggest that instead of having an itsy-bitsy $.38 stock you are going to have 2 itsy-bitsy $.20 stocks. One is probably going to be dealing with sleep apnea type stuff and the other with the traditional home monitoring, which is still really experimental. He would probably underweight this until he could see the whites of their eyes.